Representing a significant economic burden on health care systems worldwide, cancer is associated with a high level of morbidity and mortality in virtually every country (Jonsson et al., 2016). Prevalence is increasing along with incidence (Siegel et al., 2015). In 2012, there were 14 million cases of diagnosed cancer patients, while the number of cancer-related deaths was estimated to be 8.2 million (McGuire, 2016). The global cancer mortality increased by 17% between 2005 and 2015 (Wang et al., 2016). During the same period the global burden of neoplasms measured in Disability Adjusted Life Years (DALYs) increased by 11.6% (Kassebaum et al., 2016). The global cancer burden will further increase in the near future, the number of new cases is projected to achieve 22.2 million by 2030 (Vineis and Wild, 2014). Societies with established health care systems dedicate significant resources to providing access to cancer diagnostics and therapies, resulting in improved life expectancy for many oncological conditions (Jonsson et al., 2016). However, extension of life implies extended use of therapies and other health care services, both being accompanied by growing patient needs (IOM, 2001; van Baal et al., 2008). There still is a large variation among nations when it comes to cancer care and nationally allocated expenditures (Luengo-Fernandez et al., 2013; Kimman et al., 2015).